PIK3CA and endometrial cancer: Although transcriptional signature pattern according to histologic grade did not identify any distinct subgroups linking any of the mutations to phenotype, PIK3CA, KRAS and FGFR2 mutations may still be of relevance for targeting novel therapeutics in endometrial cancer.